Partnership Events
Join us for these co-hosted events!
Activity Description
Wet age-related macular degeneration (AMD) is the leading cause of severe visual impairment and legal blindness in patients
over the age of 65 years. Over the past two decades, anti–vascular endothelial growth factor (VEGF) agents have transformed the
management of wet AMD, and these agents are credited with unprecedented improvements in vision preservation and quality
of life for millions of patients in the United States and globally. Unfortunately, evidence suggests that real-world outcomes lag
behind the dramatic results often demonstrated in clinical trials, and this is often due to the high treatment burden associated
with traditional anti-VEGF therapies. Fortunately, novel therapies are now available and in development that decrease the
treatment burden by extending the dosing interval while maintaining a favorable safety profile. Thus, it is of vital importance that
ophthalmologists and retina specialists remain abreast of the latest updates on these therapies and are able to integrate them
into clinical practice. In this PeerView Live meeting series, a faculty expert will provide a concise update on the latest evidence
supporting new and emerging therapies to optimize the management of wet AMD, along with practical expert guidance needed
for clinicians to acquire the skills and strategies necessary to deliver high-quality, evidence-based, and individually-tailored care
that recognizes the unique needs and preferences of every patient.
Educational Objectives
Upon completion of this activity, participants should be better able to:
• Recognize patient- and treatment-related factors associated with suboptimal anti-VEGF treatment outcomes in patients with
wet AMD
• Assess the latest clinical data (eg, efficacy, safety, maximum effective dosing interval) for novel wet AMD treatment options
• Select appropriate therapy for patients with wet AMD based on agent and patient characteristics, and with consideration of
patient preferences
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation
Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the
American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity
AMERICANS WITH DISABILITIES ACT POSITION STATEMENT
NAEPS supports the Americans with Disabilities Act. Should you require a specific accommodation or service to facilitate your participation in our events, please send a message to Carmen Chinchilla at carmencg@nebmed.org
